CN1623550A - Hydroxy progesterone caproate oral preparation and its use - Google Patents
Hydroxy progesterone caproate oral preparation and its use Download PDFInfo
- Publication number
- CN1623550A CN1623550A CNA2003101155957A CN200310115595A CN1623550A CN 1623550 A CN1623550 A CN 1623550A CN A2003101155957 A CNA2003101155957 A CN A2003101155957A CN 200310115595 A CN200310115595 A CN 200310115595A CN 1623550 A CN1623550 A CN 1623550A
- Authority
- CN
- China
- Prior art keywords
- hydroxyprogesterone caproate
- oral
- injection
- oral formulations
- bioavailability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 title claims abstract description 50
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 title claims description 51
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000003814 drug Substances 0.000 claims abstract description 29
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000007901 soft capsule Substances 0.000 claims abstract description 3
- 238000002347 injection Methods 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000001647 drug administration Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000008899 Habitual abortion Diseases 0.000 claims description 2
- 208000019255 Menstrual disease Diseases 0.000 claims description 2
- -1 electuary Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000006196 drop Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 206010027514 Metrorrhagia Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229960004616 medroxyprogesterone Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QRDYCDIUGUAUBZ-SRWWVFQWSA-N (7r,8s,9s,10r,13s,14s,17s)-17-acetyl-7-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QRDYCDIUGUAUBZ-SRWWVFQWSA-N 0.000 description 1
- DXNJBNPIVVOILB-QCGOMIHKSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-4-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=C(O)C(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 DXNJBNPIVVOILB-QCGOMIHKSA-N 0.000 description 1
- PWCLWZOSAFOXFL-UHPWKVKZSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C(O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 PWCLWZOSAFOXFL-UHPWKVKZSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2003101155957A CN1623550A (en) | 2003-12-04 | 2003-12-04 | Hydroxy progesterone caproate oral preparation and its use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2003101155957A CN1623550A (en) | 2003-12-04 | 2003-12-04 | Hydroxy progesterone caproate oral preparation and its use |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1623550A true CN1623550A (en) | 2005-06-08 |
Family
ID=34760503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003101155957A Pending CN1623550A (en) | 2003-12-04 | 2003-12-04 | Hydroxy progesterone caproate oral preparation and its use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1623550A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140064819A (en) * | 2011-07-28 | 2014-05-28 | 리포신 인코포레이티드 | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
CN107847506A (en) * | 2015-06-22 | 2018-03-27 | 来普卡公司 | Orally administered composition and correlation technique containing 17 Gestageno Gadors |
CN112656801A (en) * | 2020-12-17 | 2021-04-16 | 深圳埃格林医药有限公司 | Use of progestagens in the treatment of cytokine release syndrome |
CN113559107A (en) * | 2020-04-28 | 2021-10-29 | 深圳埃格林医药有限公司 | Application of progestogen in preparing medicine for inhibiting cell factor storm |
WO2022117004A1 (en) * | 2020-12-01 | 2022-06-09 | 深圳埃格林医药有限公司 | Treatment method for interstitial pneumonia |
WO2022188850A1 (en) * | 2021-03-11 | 2022-09-15 | 深圳埃格林医药有限公司 | Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof |
CN115463217A (en) * | 2021-06-11 | 2022-12-13 | 深圳埃格林医药有限公司 | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
CN116077416A (en) * | 2021-11-05 | 2023-05-09 | 深圳埃格林医药有限公司 | Novel oral preparation containing progestogen and preparation method and application thereof |
-
2003
- 2003-12-04 CN CNA2003101155957A patent/CN1623550A/en active Pending
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
CN108514545A (en) * | 2011-07-28 | 2018-09-11 | 来普卡公司 | Include the Orally administered composition and correlation technique of 17- Gestageno Gadors |
EP2736515A4 (en) * | 2011-07-28 | 2014-12-24 | Lipocine Inc | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
EP3763360A1 (en) * | 2011-07-28 | 2021-01-13 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US9358298B2 (en) | 2011-07-28 | 2016-06-07 | Lipocine Inc. | 17-hydroxyprogesterone ester containing oral compositions and related methods |
US9358299B2 (en) | 2011-07-28 | 2016-06-07 | Lipocine Inc | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US9364547B2 (en) | 2011-07-28 | 2016-06-14 | Lipocine Inc. | 17-hydroxyprogesterone ester containing oral compositions and related methods |
CN103826640A (en) * | 2011-07-28 | 2014-05-28 | 来普卡公司 | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US9399069B2 (en) | 2011-07-28 | 2016-07-26 | Lipocine Inc. | 17-Hydroxyprogesterone ester containing oral compositions and related methods |
AU2012286620B2 (en) * | 2011-07-28 | 2017-08-24 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
JP2017193554A (en) * | 2011-07-28 | 2017-10-26 | リポカイン インコーポレーテッド | Oral composition comprising 17-hydroxyprogesterone ester and related method |
US10709716B2 (en) | 2011-07-28 | 2020-07-14 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US10022384B2 (en) | 2011-07-28 | 2018-07-17 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
KR20140064819A (en) * | 2011-07-28 | 2014-05-28 | 리포신 인코포레이티드 | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US11471470B2 (en) | 2011-07-28 | 2022-10-18 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
JP2014521660A (en) * | 2011-07-28 | 2014-08-28 | リポカイン インコーポレーテッド | Oral compositions containing 17-hydroxyprogesterone esters and related methods |
CN107847506A (en) * | 2015-06-22 | 2018-03-27 | 来普卡公司 | Orally administered composition and correlation technique containing 17 Gestageno Gadors |
US11590147B2 (en) | 2015-06-22 | 2023-02-28 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
CN113559107B (en) * | 2020-04-28 | 2023-01-06 | 深圳埃格林医药有限公司 | Application of progestogen in preparing medicine for inhibiting cell factor storm |
CN113559107A (en) * | 2020-04-28 | 2021-10-29 | 深圳埃格林医药有限公司 | Application of progestogen in preparing medicine for inhibiting cell factor storm |
WO2022117004A1 (en) * | 2020-12-01 | 2022-06-09 | 深圳埃格林医药有限公司 | Treatment method for interstitial pneumonia |
CN112656801A (en) * | 2020-12-17 | 2021-04-16 | 深圳埃格林医药有限公司 | Use of progestagens in the treatment of cytokine release syndrome |
WO2022188850A1 (en) * | 2021-03-11 | 2022-09-15 | 深圳埃格林医药有限公司 | Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof |
CN115068487A (en) * | 2021-03-11 | 2022-09-20 | 深圳埃格林医药有限公司 | Antitumor combined preparation containing hydroxyprogesterone caproate and application thereof |
CN115068487B (en) * | 2021-03-11 | 2024-01-30 | 深圳埃格林医药有限公司 | Antitumor combination preparation containing hydroxyprogesterone caproate and application thereof |
EP4338742A4 (en) * | 2021-06-11 | 2024-08-21 | Shenzhen Evergreen Therapeutics Co Ltd | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
CN115463217B (en) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
CN115463217A (en) * | 2021-06-11 | 2022-12-13 | 深圳埃格林医药有限公司 | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
CN116077416A (en) * | 2021-11-05 | 2023-05-09 | 深圳埃格林医药有限公司 | Novel oral preparation containing progestogen and preparation method and application thereof |
WO2023078073A1 (en) * | 2021-11-05 | 2023-05-11 | 深圳埃格林医药有限公司 | Novel oral preparation containing progestogen, and preparation method and use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107213149B (en) | Application of artemisinin derivatives in preparation of drugs for treating or assisting in treating autoimmune thyroid diseases | |
CN1623550A (en) | Hydroxy progesterone caproate oral preparation and its use | |
CN101502579B (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
CN1210289C (en) | Radde anemone rhizome extract and its prepn process and use | |
CN102091111A (en) | Saussurea cataplasm and production method thereof | |
CN101074255A (en) | Preparation of hemsleyadine-A and its use of preparing pharmaceutics against cancers | |
CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
CN101011545A (en) | Method for extracting effective sites group of smilax China root | |
CN1883566A (en) | Anti-inflammation medicine and method for preparing same | |
CN101209299B (en) | Chinese medicinal composition for treating pelvic inflammatory disease and extracting method thereof | |
CN103006789A (en) | Preparation method of Glossy privet fruit and radix astragali sustained release preparations and product | |
CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
CN100348228C (en) | New use of powder for regulating liver and spleen and its active part | |
CN1836665A (en) | Pharmaceutical uses of hesperidin or its composition | |
CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
CN102813873A (en) | Traditional Chinese medicine composition for treating mental diseases, and preparation method, application and quality control thereof | |
CN101468133A (en) | Pharmaceutical composition for treating inflammation of gynecology | |
CN104739949A (en) | Composition for treating Parkinson disease and preparation method of composition | |
CN116270632B (en) | A herba Achillea Wilsonianae alkaloid composition with detoxified effect and its preparation method | |
CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof | |
CN102631419B (en) | Medicine composition for treating gout, as well as preparation method and application of medicine composition | |
CN101549032A (en) | Drug composition with the effect of anti-lung cancer and application in preparing anti-lung cancer drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING JINGWEI YANKANG PHARMACEUTICALS RESEARCH Free format text: FORMER OWNER: ZHANG WEI; APPLICANT Effective date: 20070907 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070907 Address after: 100070 Beijing city Fengtai District Haiying Road No. 3 Applicant after: Beijing Jingwei Yankang Pharmaceutical Research Institute Co., Ltd. Address before: 100850 C, gate 49, 27 Taiping Road, Beijing, Haidian District 1401, China Applicant before: Zhang Wei Co-applicant before: Zhang Zuoyun |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |